Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro

Endocrine-Related Cancer

Volumn 19, Issue 1, 2012, Pages 29-38

  Koh, Yoon Woo ^a,b   Shah, Manisha H ^a   Agarwal, Kitty ^a   McCarty, Samantha K ^a   Koo, Bon Seok ^a,c   Brendel, Victoria J ^a   Wang, Chaojie ^a   Porter, Kyle ^a   Jarjoura, David ^a   Saji, Motoyasu ^a   Ringel, Matthew D ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EVEROLIMUS; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SELUMETINIB; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN RET; PYRIDINE DERIVATIVE; RAPAMYCIN; RET PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; ASSAY; CELL SURVIVAL; DRUG POTENTIATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; THYROID MEDULLARY CARCINOMA; WESTERN BLOTTING; CARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BENZIMIDAZOLES; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; SIROLIMUS; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84860380245     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0155     Document Type: Article

References (22)

1. Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC & Powell MB 2004 Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Research 64 2552-2560. (doi:10.1158/0008-5472.CAN-03-3327)
2. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI &Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. Journal of Clinical Endocrinology and Metabolism 95 2588-2595. (doi:10.1210/jc.2009-1923)
3. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM & Santoro M 2006 BAY43-9006 inhibition of oncogenic RET mutants. Journal of National Cancer Institute 98 326-334. (doi:10.1093/jnci/djj069)
4. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC et al. 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 118 3065-3074. (doi:10.1172/JCI34739)
5. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Journal of the American Medical Association 276 1575-1579. (doi:10.1001/jama.1996. 03540190047028)
6. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR et al. 2004 The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. Journal of Cell Biology 166 213-223. (doi:10.1083/jcb.200403069)
7. Harrington LS, Findlay GM & Lamb RF 2005 Restraining PI3K: mTOR signalling goes back to the membrane. Trends in Biochemical Sciences 30 35-42. (doi:10.1016/j.tibs.2004.11.003)
8. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A et al. 2010 AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). Journal of Hepatology 52 79-87. (doi:10.1016/j.jhep.2009.10.008)
9. Jin N, Jiang T, Rosen DM, Nelkin BD & Ball DW 2009 Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 94 4107-4112. (doi:10.1210/jc.2009-0662)
10. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C et al. 2008 Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. Journal of Clinical Investigation 118 3051-3064. (doi:10.1172/JCI34764)
11. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M et al. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19 565-612. (doi:10.1089/thy.2008.0403)
12. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV et al. 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 28 2323-2330. (doi:10.1200/JCO.2009.25.0068)
13. Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Perez-Soler R, Horwitz SB & McDaid HM 2007 Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Research 67 11300-11308. (doi:10.1158/0008-5472.CAN-07-0702)
14. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508. (doi:10.1158/0008-5472.CAN-05-2925)
15. Poulikakos PI, Zhang C, Bollag G, Shokat KM & Rosen N 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464 427-430. (doi:10.1038/nature08902)
16. Shah OJ, Wang Z & Hunter T 2004 Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Current Biology 14 1650-1656. (doi:10.1016/j.cub. 2004.08.026)
17. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 94 1493-1499. (doi:10.1210/jc.2008-0923)
18. Wells SA Jr & Santoro M 2009 Targeting the RET pathway in thyroid cancer. Clinical Cancer Research 15 7119-7123. (doi:10.1158/1078-0432.CCR-08- 2742)
19. Yang S, Ngo VC, Lew GB, Chong LW, Lee SS, Ong WJ, Lam WL, Thng CH, Koong HN, Ong HS et al. 2009 AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Molecular Cancer Therapeutics 8 2537-2545. (doi:10.1158/1535-7163.MCT-09-0213)
20. Ye L, Santarpia L & Gagel RF 2010 The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocrine Reviews 31 578-599. (doi:10.1210/er.2009-0031)
21. Yoon YK, Kim HP, Han SW, Hur HS, Oh DY, Im SA, Bang YJ & Kim TY 2009 Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Molecular Cancer Therapeutics 8 2526-2536. (doi:10.1158/1535-7163.MCT-09-0300)
22. Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O'Brien-Jenkins A, Katsaros D et al. 2007 Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clinical Cancer Research 13 5314-5321. (doi:10.1158/1078-0432.CCR-06-2660)